Skip to main content
SpringerLink
Log in

Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers

  • News and Views
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

An Erratum to this article was published on 03 March 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Penot A, Preux PM, Le Guyader S et al (2015) Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980–2009. Leuk Lymphoma 56:1771–1777

    Article  PubMed  Google Scholar 

  2. Palani R, Milojkovic D, Apperley JF (2015) Managing pregnancy in chronic myeloid leukaemia. Ann Hematol 94(suppl 2):S167–S176

    Article  PubMed  Google Scholar 

  3. Mariani S, Basciani S, Fabbri A et al (2011) Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertil Steril 95:1120.e15–1120.e17

    Article  Google Scholar 

  4. Abruzzese E, Trawinska MM, de Fabritiius P et al (2016) Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol 9(8):781–791

    Article  CAS  PubMed  Google Scholar 

  5. EUROCAT Prevalence Tables (2008–2012). [Online] http://www.eurocat-network.eu/ACCESSPREVALENCEDATA/PrevalenceTables. Accessed on 25 Sept 2015

  6. Guerci-Bresler A, Huguet F, Legros L et al (2011) Fertilité, grossesse, allaitement et état de santé des nouveau-nés chez les patient(e)s souffrant de LMC-PC et traité(e)s par inhibiteurs de la tyrosine kinase. Recommandations du groupe Fi-LMC. Correspondances en Onco-hématologie vol VI-no2:92–102

Download references

Acknowledgements

The French Network Pharmacovigilance Centers is aknowledged.

Author information

Authors and Affiliations

  1. Centre régional de Pharmacovigilance, Hôpital Fernand-Widal,AP-HP, Paris, France

    Patrick Carlier & Pirayeh Eftekhari

  2. Centre régional de Pharmacovigilance, Hospices Civils de Lyon, Lyon, France

    Nathalie Bernard

  3. Centre régional de Pharmacovigilance, CHRU Angers, Angers, France

    Laurence Lagarce

  4. Centre régional de Pharmacovigilance, CHU Dijon, Dijon, France

    Anne Dautriche

  5. Centre régional de Pharmacovigilance du Nord Pas de Calais, CHU Lille, 59000, Lille, France

    Johana Béné

  6. Centre régional de Pharmacovigilance, CHU Grenoble Alpes, Grenoble, France

    Nathalie Fouilhé Sam-Lai

Authors
  1. Patrick Carlier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathalie Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laurence Lagarce
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anne Dautriche
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Johana Béné
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nathalie Fouilhé Sam-Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pirayeh Eftekhari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Carlier.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s00404-017-4321-0.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carlier, P., Bernard, N., Lagarce, L. et al. Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers. Arch Gynecol Obstet 295, 269–271 (2017). https://doi.org/10.1007/s00404-016-4262-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-016-4262-z

Keywords

Search

Navigation